Development of Casein Kinase 1d and 1e Inhibitors for Treatment of Brain Cancer
Development of Casein Kinase 1d and 1e Inhibitors for Treatment of Brain Cancer
批准号:
9249390
负责人:
Andrii Monastyrskyi
金额:
$5.71万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-04-01 至 2018-03-31
关键词:
Active Biological TransportAdultAffectAnimal ModelApoptosisBioavailableBiochemicalBiochemistryBiologicalBiological AssayBiological AvailabilityBlood - brain barrier anatomyBrainBrain NeoplasmsCancer BiologyCancer EtiologyCancer ModelCancer PatientCell LineCellsCentral Nervous System NeoplasmsCessation of lifeChemicalsCollaborationsComputer SimulationCranial IrradiationDataDevelopmentDiagnosisDialysis procedureDiffusionDiseaseDistantDrug KineticsERBB2 geneEffectivenessEquilibriumExcisionFDA approvedFloridaGlioblastomaGoalsHumanIn VitroKineticsLaboratoriesLeadLife ExpectancyLungMDA MB 231Malignant - descriptorMalignant GliomaMalignant NeoplasmsMalignant neoplasm of brainMetastatic malignant neoplasm to brainModernizationModificationMusNatureNeoplasm MetastasisOralOutcomePatientsPenetrationPharmaceutical ChemistryPharmaceutical PreparationsPositioning AttributePropertyPurine AntagonistPurinesRecurrent tumorRefractoryResearch InstituteResistanceRoleSeriesSignal PathwayStructureSurgically-Created Resection CavityTherapeuticWorkXenograft Modelanalogbasebeta cateninbrain surgerybrain tissuecarrier mediated transportcasein kinasecasein kinase Ichemotherapyclinical applicationdesigndrug metabolismeffective therapyhigh throughput screeningimprovedin vivoin vivo Modelinhibitor/antagonistinsightirradiationmalignant breast neoplasmneoplastic cellnoveloutcome forecastoverexpressionpalliativepreclinical developmentpublic health relevancescaffoldsmall moleculetargeted deliverytooltreatment strategytumoruptake
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Highly potent and selective inhibitors of casein kinase 1 delta (CK1δ) and 1 epsilon (CK1ε) were recently identified as a result of high-throughput screening and medicinal chemistry optimization in the Roush laboratory at The Scripps Research Institute Florida. Preliminary studies indicate that this class of purine inhibitors is ideally suited to serve as probes to define the roles of CK1δ/CK1ε in a host of human cancers. Despite exceptional effectiveness of the current lead compound in animal models, the brain penetration of the lead agent is only 12% which is not suitable for clinical applications for treatment of brain cancer. Although considerable progress has been recently made in the treatment brain tumors, the most effective treatment options remain whole-brain radiation and surgery while medication is mostly palliative or supportive in nature. Iterative medicinal chemistry and DMPK parameters will be used to develop safe, potent, orally bioavailable and brain penetrant CK1δ/CK1ε inhibitors for treating primary and metastatic brain cancer.
Using in-house SAR and DMPK data accompanied with in silico analysis of brain penetration properties, the design of new purine inhibitors for targeted delivery through the blood-brain barrier (BBB) will be accomplished. Firstly, the development of CK1δ/ε analogs with improved physicochemical properties to enhance passive BBB diffusion will be pursed. Furthermore, the design and synthesis of purine derivatives for active transport by small molecule transporters presented in BBB will be accomplished by chemical modification at C2 and C6 positions by addition of endogenous carrier substrate-like moieties via adjustable linkers.
With only a handful compounds approved by the FDA for treatment of brain cancer, completion of the proposed work will provide with a novel series of inhibitors capable of producing a significant impact on the thousands affected by this horrific disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Integrated fragment-based phenotypic screening and chemoproteomics for identification of novel small cell lung cancer-specific targets
-
批准号:10577507
-
项目类别:
-
资助金额:$23.63万
-
财政年份:2023
-
负责人:Andrii Monastyrskyi
-
依托单位:
Development of Casein Kinase 1d and 1e Inhibitors for Treatment of Brain Cancer
-
批准号:9045946
-
项目类别:
-
资助金额:$5.43万
-
财政年份:2016
-
负责人:Andrii Monastyrskyi
-
依托单位:
海外基金